BIIB vs TBI · P/E 21, rev $9.89B vs rev $841.6M
Biogen Inc (BIIB) versus TrueBlue Inc (TBI) — a side-by-side from cached financials, not a winner call.
Biogen Inc (BIIB) is a drug manufacturers - general company listed on NASDAQ. It is led by Christopher A. Viehbacher.
TrueBlue Inc (TBI) is a staffing & employment services company listed on NYSE.
Latest reported BIIB revenue for 2025-12-31 was $9.89B. Net income was $1.29B. Revenue was up 2.2% from 2024-12-31 to 2025-12-31. BIIB currently screens at market cap $29.33B and trailing P/E 21.4.
Latest reported TBI revenue for 2026-06-28 was $841.6M. Net income was -$23.2M. TBI currently screens at market cap $205.8M.
BIIB currently screens at market cap $29.33B and trailing P/E 21.4. TBI currently screens at market cap $205.8M.
Not investment advice. Open the BIIB and TBI stock pages for the full models.
Not investment advice.